and it has now become a minority therapeutic option. In the current issue of Thorax a systematic review is presented which argues against its continuation as an option for the management of persistent symptoms in childhood. 5 Why has it taken so long for the evidence of few, if any, beneficial eVects in the management of persistent childhood asthma to appear in the face of its virtual disappearance from the prescribing armamentarium? What lessons can be drawn from the now passing cromoglycate era?
In the years immediately after introduction to the market of any new therapeutic agent and when interest is intense it is likely that the evidence presented to the prescribing community is selective. Indeed, the present review provides evidence for this as the older studies were more likely to show a beneficial eVect than those performed in recent years. 5 The paucity of data in very young children in the early years of the cromoglycate era is not unique to this single therapeutic agent. A large amount of "oV label" and unlicensed prescribing is commonplace in childhood and this is more acute in the younger child population where clinical trial data are sparse. 6 This can clearly be seen in the present review as studies in younger children only began to appear in more recent years when studies designed by practising clinicians with or without industry support sought to correct this deficiency. For asthma and wheezing illness the paucity of clinical trial data is particularly frustrating as most childhood asthma presents in the first four years of life. Consequently, it is in this youngest age group that extrapolation from trial data in older children and adults is required, which clearly presents a problem for practitioners wishing to engage in evidence based prescribing.
Although meta-analyses such as that reported in the current issue 5 are essential, practitioners managing childhood asthma must also pay close attention to both the quality of the studies included in such an analysis and also whether the patients included in the published trials describe the kind of patients typically seen in their surgery or clinic. As most recruitment to clinical trials is based in hospital clinics while the majority of patients are managed in primary care, this poses a problem in generalising results from what are likely to be the relatively small proportion of more severely aVected individuals to the majority with mild to moderate disease. Inclusion of less severely aVected individuals from primary care in order to assess established therapeutic approaches has resulted in rather diVerent outcomes from those found in more severely aVected hospital based populations and from studies in adult populations. 7 8 Studies required for licensing purposes are required to demonstrate eYcacy by comparing "hard" outcomes such as peak expiratory flow rate or forced expiratory volume in one second against placebo. Such studies are tightly regulated and are usually associated with a significant benefit for placebo, a likely consequence of improved compliance with treatment during the close monitoring required during such trials. Such tightly regulated conditions are far removed from the real world where compliance with treatment is generally poor, even when entirely supervised by parents. 9 Added to this problem are patient/parent preferences and selective administration. Although the side eVects of cromoglycate appear to be minor, it is likely that they have a significant impact on compliance with treatment. These side eVects include an unpleasant bitter taste and upper respiratory tract irritation including cough soon after administration. 5 In combination with the 3-4 times a day regime required for maximum benefit, it is no wonder that this treatment has become unpopular with children, parents, and prescribers.
The evidence for the eYcacy and overall eVectiveness (eYcacy × compliance) of cromoglycate in persistent childhood asthma is weak. However, its role in exercise induced bronchoconstriction has not been addressed in the current review and it is likely that this will remain an option for this particular feature of asthma. Rather than waiting for more than 30 years for evidence of eVectiveness in the youngest age group of children which make up so much of the work load in primary 10 and secondary care, 11 further studies on the eVectiveness of more recently introduced formulations such as long acting agonists and leukotriene receptor antagonists need to be performed, particularly in young children, in order to inform evidence based guidelines and support good prescribing practice.
Recent changes in legislation on drug licensing in the United States 12 and recommendations from the Committee for Proprietary Medical Products (CPMP) of the European Union 13 should provide a stimulus for further studies in children of all ages and particularly in the youngest age groups where data are particularly sparse. 
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